The influence of FDA advisory information and black box warnings on individual use of prescription antidepressants
- 378 Downloads
We examine how use of antidepressant medications is influenced by Food and Drug Administration (FDA) warnings about the increased risk of suicidality associated with pediatric antidepressant use. With individual-level data on antidepressant use from the Medical Expenditure Panel Survey, we consider whether consumer responses to FDA warnings differ among targeted (children) and non-targeted (adult) age-groups. Because the warning labels specifically mentioned new users, we examine separately the effects of the warnings on initiations of antidepressant therapy and on continued use of antidepressants. We find evidence consistent with reduced initiation of antidepressant use among the intended population of children, and that usage among children with more highly educated parents responded earlier to FDA information. However, we also find spillover effects of reduced initiation among the non-targeted population of adults. Overall, our results indicate that the FDA warning may have led consumers to perceive risks beyond those specifically mentioned.
KeywordsWarning labels Prescription use Antidepressants FDA
JEL ClassificationI11 I18 D83 M38
- Bettman, J. R., Payne, J. W., & Staelin, R. (1986). Cognitive considerations in designing effective labels for presenting risk information. Journal of Public Policy and Marketing, 5, 1–28.Google Scholar
- Busch, S. H., Frank, R. G., Martin, A., & Barry, C. (2010). Characterizing declines in pediatric antidepressant use after new risk disclosures. Medical Care Research and Review (advance online publication, July 30, 2010).Google Scholar
- Food and Drug Administration. (2003). FDA public health advisory. Food and Drug Administration. http://www.fda.gov/CDER/drug/advisory/mdd.htm.
- Food and Drug Administration. (2004). FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medications. Press release October 15, 2004. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108363.htm.
- Linsenmayer, M., Scheffrahn, M., McLain, M. E., & Brenner, D. (1999). Frequency and demographics of depression: A study of the UT-Austin GSLIS student population. Austin, TX: University of Texas-Austin.Google Scholar
- Lleras-Muney, A., & Lichtenberg, F. R. (2003). The effect of education on medical technology adoption: Are the more educated more likely to use new drugs? National Bureau of Economic Research. http://www.nber.org/CRIW/papers/lleras.pdf.
- McKeown, R., Cuffe, S., & Schulz, R. (2006). US suicide rates by age group, 1970–2002: An examination of recent trends. American Journal of Public Health, 96, 1744–1751.Google Scholar
- Parkinson, K., Price, J., Simon, K. I., & Tennyson, S. (2008). The influence of FDA advisory information and black box warnings on consumer use of prescription antidepressants (October 29, 2008). SSRN working paper #1292082.Google Scholar
- Sharp, I. R., & Chapman, J. E. (2004). Antidepressants and increased suicidality: The media portrayal of controversy. The Scientifc Review of Mental Health Practice, 3.Google Scholar
- Soumerai, S. B. (2004). Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Affairs, 23(1), 135–146.Google Scholar
- Stewart, D. W., & Martin, I. M. (1994). Intended and unintended consequences of warning messages: A review and synthesis of empirical research. Journal of Public Policy & Marketing, 13(Spring), 1–19.Google Scholar